Off-label drugs use in pediatric palliative care
| Autor: | Egidio Barbi, Lucia De Zen, Franca Benini, Federico Marchetti |
|---|---|
| Přispěvatelé: | De Zen, Lucia, Marchetti, Federico, Barbi, Egidio, Benini, Franca |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Palliative care Pain Context (language use) Off-label use Scientific evidence 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) 030225 pediatrics medicine Humans 030212 general & internal medicine Medical prescription Child Intensive care medicine business.industry Palliative Care lcsh:RJ1-570 lcsh:Pediatrics Off-Label Use Pediatric palliative care Off-label drugs Clinical trial Off-label drug Italy Commentary business |
| Zdroj: | Italian Journal of Pediatrics Italian Journal of Pediatrics, Vol 44, Iss 1, Pp 1-6 (2018) |
| DOI: | 10.1186/s13052-018-0584-8 |
| Popis: | Background Paediatric palliative care (PPC) aim to ensure the control of symptoms and the best possible quality of life for patients whose underlying disease, characterized by an unstoppable evolution and negative prognosis, no longer responds to specific treatments. The scientific evidence in this context are very deficient and, in order to obtain welfare objectives consistent with the situation, in the overwhelming majority of cases the prescription of drugs is off-label for indication of use and/or for age and/or for way of administration and/or formulation. The Agenzia Italiana del Farmaco - AIFA and the Italian Society of Palliative Care (Società Italiana di Cure Palliative - SICP), under a dedicated working group, wrote a document that collects the scientific evidence available to support the off-label use of medicines more frequently used in PPC. The goal is to certify the consolidated off-label use of these drugs and propose their use under the Law 648/96, in the absence of data from its pivotal clinical trials. Aim of the commentary is to report the conditions for this important work and to present the 10 drugs, usually used off-label in PPC and in pain therapy, now included in Law 648/96. Conclusion This work is deemed essential to resolve, at least in part, the lack of availability of medicines researched and approved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|